Noile-Immune Biotech Inc. (4893.T)
JPY 137.0
(-0.72%)
JPY 137.0
(-0.72%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 5.77 Billion JPY | 24.52% |
| 2022 | 4.64 Billion JPY | 8.66% |
| 2021 | 4.27 Billion JPY | 59.71% |
| 2020 | 2.67 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 5.45 Billion JPY | -5.57% |
| 2024 Q2 | 5.08 Billion JPY | -6.77% |
| 2023 Q3 | 6.16 Billion JPY | 0.6% |
| 2023 FY | 5.77 Billion JPY | 24.52% |
| 2023 Q1 | 4 Billion JPY | -13.63% |
| 2023 Q2 | 6.13 Billion JPY | 52.99% |
| 2023 Q4 | 5.77 Billion JPY | -6.32% |
| 2022 Q4 | 4.64 Billion JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | 12.298% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -377.037% |
| GNI Group Ltd. | 62.39 Billion JPY | 90.738% |
| Linical Co., Ltd. | 18.53 Billion JPY | 68.83% |
| Trans Genic Inc. | 9.81 Billion JPY | 41.097% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | -2.57% |
| Soiken Holdings Inc. | 6.94 Billion JPY | 16.803% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | 0.643% |
| AnGes, Inc. | 28.89 Billion JPY | 79.998% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -566.334% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 96.324% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -257.038% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | -13.954% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | -32.853% |
| CanBas Co., Ltd. | 2.43 Billion JPY | -137.538% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | -143.491% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | 16.613% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -229.951% |
| Kidswell Bio Corporation | 5.08 Billion JPY | -13.635% |
| PeptiDream Inc. | 67.12 Billion JPY | 91.391% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | -183.199% |
| Ribomic Inc. | 3.54 Billion JPY | -62.913% |
| SanBio Company Limited | 5.04 Billion JPY | -14.496% |
| Healios K.K. | 15.15 Billion JPY | 61.868% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -369.735% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | -91.61% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -292.018% |
| StemRIM | 9.08 Billion JPY | 36.355% |
| CellSource Co., Ltd. | 6.87 Billion JPY | 16.0% |
| FunPep Company Limited | 2.49 Billion JPY | -131.981% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | -120.684% |
| Stella Pharma Corporation | 3.82 Billion JPY | -51.257% |
| TMS Co., Ltd. | 3.55 Billion JPY | -62.57% |
| Cuorips Inc. | 6.18 Billion JPY | 6.561% |
| K Pharma,Inc. | 3.31 Billion JPY | -74.385% |
| Takara Bio Inc. | 123.2 Billion JPY | 95.31% |
| ReproCELL Incorporated | 9.05 Billion JPY | 36.163% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | -112.827% |
| StemCell Institute Inc. | 6.54 Billion JPY | 11.678% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | 17.311% |
| CellSeed Inc. | 2.46 Billion JPY | -134.367% |